AU2017317575B2 - Treatment of nonalcoholic fatty liver disease - Google Patents

Treatment of nonalcoholic fatty liver disease Download PDF

Info

Publication number
AU2017317575B2
AU2017317575B2 AU2017317575A AU2017317575A AU2017317575B2 AU 2017317575 B2 AU2017317575 B2 AU 2017317575B2 AU 2017317575 A AU2017317575 A AU 2017317575A AU 2017317575 A AU2017317575 A AU 2017317575A AU 2017317575 B2 AU2017317575 B2 AU 2017317575B2
Authority
AU
Australia
Prior art keywords
compound
dose
inhibitor
pde4
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017317575A
Other languages
English (en)
Other versions
AU2017317575A1 (en
Inventor
Yuichiro Amano
Guido Hanauer
Hiroshi Nagabukuro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2017317575A1 publication Critical patent/AU2017317575A1/en
Application granted granted Critical
Publication of AU2017317575B2 publication Critical patent/AU2017317575B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: TAKEDA GMBH
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017317575A 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease Active AU2017317575B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662380004P 2016-08-26 2016-08-26
US62/380,004 2016-08-26
PCT/EP2017/071418 WO2018037109A1 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
AU2017317575A1 AU2017317575A1 (en) 2019-03-28
AU2017317575B2 true AU2017317575B2 (en) 2021-10-14

Family

ID=59699703

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017317575A Active AU2017317575B2 (en) 2016-08-26 2017-08-25 Treatment of nonalcoholic fatty liver disease

Country Status (7)

Country Link
US (1) US11179384B2 (OSRAM)
EP (1) EP3503892A1 (OSRAM)
JP (1) JP7048863B2 (OSRAM)
CN (1) CN110099686B (OSRAM)
AU (1) AU2017317575B2 (OSRAM)
CA (1) CA3034956C (OSRAM)
WO (1) WO2018037109A1 (OSRAM)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
US8324391B2 (en) * 2004-03-03 2012-12-04 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
WO2017017165A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101133045A (zh) * 2005-03-02 2008-02-27 尼科梅德有限责任公司 6-杂环基取代的六氢菲啶衍生物的新盐类
NZ589278A (en) 2005-03-02 2012-04-27 Nycomed Gmbh Selected salts of 6-heterocyclyl substituted hexahydrophenanthridine derivatives
UA100497C2 (ru) * 2006-09-07 2013-01-10 Никомед Гмбх Комбинированное лечение сахарного диабета
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
US20160339010A1 (en) * 2014-01-22 2016-11-24 Takeda Gmbh Treatment of Partly Controlled or Uncontrolled Severe Asthma
US10300042B2 (en) * 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
US8324391B2 (en) * 2004-03-03 2012-12-04 Nycomed Gmbh Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors
WO2009109525A1 (en) * 2008-03-03 2009-09-11 Nycomed Gmbh Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
WO2017017165A1 (en) * 2015-07-29 2017-02-02 Takeda Gmbh Pde4 inhibitor for the treatment of diabetic nephropathy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. F. M. WOUTERS ET AL, JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, US, (2012-09-01), vol. 97, no. 9, doi:10.1210/jc.2011-2886, ISSN 0021-972X, pages E1720 - E1725 *
FERNANDEZ-MARTINEZ E ET AL, EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, JENA, DE, vol. 61, no. 5, doi:10.1016/J.ETP.2008.11.001, ISSN 0940-2993, (2008-12-17), pages 471 - 479, (2008-12-17) *
L. GOBEJISHVILI ET AL, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, (2013-07-25), vol. 347, no. 1, doi:10.1124/jpet.113.204933, pages 80 - 90 *
VOLLERT S ET AL, DIABETOLOGIA ; CLINICAL AND EXPERIMENTAL DIABETES AND METABOLISM, SPRINGER, BERLIN, DE, (2012-07-13), vol. 55, no. 10, doi:10.1007/S00125-012-2632-Z, ISSN 1432-0428, pages 2779 - 2788 *

Also Published As

Publication number Publication date
EP3503892A1 (en) 2019-07-03
CA3034956C (en) 2024-10-29
JP2019524860A (ja) 2019-09-05
US11179384B2 (en) 2021-11-23
WO2018037109A1 (en) 2018-03-01
CN110099686A (zh) 2019-08-06
AU2017317575A1 (en) 2019-03-28
CA3034956A1 (en) 2018-03-01
JP7048863B2 (ja) 2022-04-06
CN110099686B (zh) 2022-04-15
US20210283122A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
US12171731B2 (en) Methods and compositions for the treatment of steatosis-associated disorders
JP6941109B2 (ja) Ｆｘｒアゴニストを使用するための方法
KR101996245B1 (ko) 선택적 s1p1 수용체 아고니스트를 포함하는 약학 조합물
KR20190101365A (ko) 바독솔론 메틸 또는 이의 유사체를 사용하는 알포트 증후군의 치료 방법
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR20190044667A (ko) Fxr 작용제의 신규 요법
Tian et al. Ephedrine alleviates bleomycin-induced pulmonary fibrosis by inhibiting epithelial-mesenchymal transition and restraining NF-κB signaling
AU2015231076B2 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
AU2022282651A1 (en) Pemafibrate and/or tofogliflozin for use in treating liver disease
AU2017317575B2 (en) Treatment of nonalcoholic fatty liver disease
US20220313622A1 (en) Phytocannabinoids for preventing or treating non-alcoholic fatty liver disease, dyslipidemia, and type 2 diabetes
WO2010007085A2 (en) Use of organic compounds
JP2020510001A (ja) 非アルコール性脂肪性肝疾患と非アルコール性脂肪性肝炎の予防および／または処置に使用するための化合物
HK40012462A (en) Treatment of nonalcoholic fatty liver disease
HK40012462B (en) Treatment of nonalcoholic fatty liver disease
EP4166137B1 (en) Therapeutic agent for fatty liver disease
TWI906348B (zh) 脂肪性肝疾病之治療劑
HK40080642A (en) Therapeutic agent for fatty liver disease
HK40089150A (en) Therapeutic agent for fatty liver disease
HK40089150B (en) Therapeutic agent for fatty liver disease
JP2004309186A (ja) 小胞体ストレスの改善剤およびその評価方法
HK40063789B (zh) 大麻素酸酯组合物及其用途
BR112020004903A2 (pt) uso de anticorpos de ligação de il-1b para o tratamento de hepatite alcoólica
JP2011032267A (ja) １１βＨＳＤ１阻害剤およびその用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER APPLICANT(S): TAKEDA GMBH